Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4081-4090 Newer>

The Motley Fool August 31, 2007 Brian Orelli	Guidelines to Stop the Wheezing Investors, new asthma guidelines will affect some drug makers. The FDA isn't the only organization that affects how well drugs do in the marketplace.
The Motley Fool August 31, 2007 Brian Lawler	QLT Gets Reformulated Drug developer QLT announced that an EU approval will open new markets for the cancer drug that could edge out the competition by lowering overall medical costs.
The Motley Fool August 31, 2007 Rich Smith	A Healthy Buyback for Medicis? Investors, can Medicis pay its own way? And even if it can, should it?
The Motley Fool August 30, 2007 Brian Lawler	Human Genome Steps Forward Human Genome Sciences investors got good news as the drugmaker took a quicker-than-expected step in its journey to get its lead drug, hepatitis C treatment Albuferon, on the path to FDA approval.
The Motley Fool August 30, 2007 Brian Orelli	Merck Tries to Stop the Flushing The FDA will review the pharma's new cholesterol drug. The biggest worry with getting CORDAPTIVE approved is probably not with its effectiveness, but with safety. Investors, take note.
The Motley Fool August 30, 2007 Brian Lawler	ImClone's Healthy Pipeline With three new molecules in phase 2 testing and another two in phase 1 testing by the end of the year, ImClone may not be completely reliant on Erbitux for its fortunes in the coming years.
The Motley Fool August 30, 2007 Brian Orelli	Forget What Your Drug Was Approved For Baxter stages a new trial for an old drug.
The Motley Fool August 29, 2007 Brian Orelli	Prevention for Your Portfolio Medicare is increasing the number of screenings tests and immunizations it pays for. Which pharmaceutical and medical companies stand to benefit from this increased spending on preventative medicine? Read on.
The Motley Fool August 29, 2007 Brian Lawler	Adolor Stays in the Ring Adolor takes another run at getting FDA approval for its lead drug. Shares of the biotech firm are up on news the FDA had accepted for review additional information about its ileus medication, Entereg.
The Motley Fool August 29, 2007 Billy Fisher	China Medical Continues to Impress China Medical Technologies, the Chinese medical device maker, produces another quarter of incredible growth, which the company attributes to momentum from its in-vitro diagnostic business.
<Older 4081-4090 Newer> Return to current articles.